Studi Pola Pemberian Artemisinin-Based Combination Therapy pada Pasien Malaria di RSUD Supiori Papua
Abstract
Malaria merupakan salah satu penyakit dengan prevalensi tinggi di Indonesia. Data Riset Kesehatan Dasar (Riskesdas) tahun 2018 menunjukkan prevalensi populasi malaria berdasarkan riwayat pemeriksaan darah tertinggi di Indonesia pada tahun 2013–2018 yaitu di Provinsi Papua. Tujuan penelitian adalah mengetahui pola pemberian dan ketepatan terapi Artemisinin based combination therapy (ACT) di RSUD Supiori, Papua. Penelitian ini merupakan penelitian deskriptif dengan pengambilan data secara retrospektif yaitu melakukan penelusuran terapi melalui rekam medis pasien dan dokumen pencatatan yang lain. Penelitian dilakukan pada periode Januari–Agustus 2019 terhadap 1.636 orang dan 71 pasien dinyatakan positif malaria. Seluruh pasien (100%) diterapi dengan Dyhidroartemisinin-piperaquin (DHP). Kasus malaria falciparum ditemukan pada 33 orang (46,48%), dan hampir seluruhnya (96,97%) diterapi dengan DHP+Primakuin. Kasus malaria vivax ditemukan pada 33 orang (46,48%), yang seluruhnya (100%) diterapi dengan DHP+Primakuin. Kasus malaria mix ditemukan pada 5 orang (7,04%), sebanyak 4 orang (80,00%) diterapi dengan DHP+Primakuin dan 1 orang (20,00%) diterapi dengan Artesunate dilanjutkan dengan DHP+Primakuin.Pola pemberian terapi malaria di RSUD Supiori pada periode Januari–Agustus 2019 telah sesuai pedoman tatalaksana malaria.
Kata kunci: Artemisinin-based combination therapy (ACT), malaria, pola pemberian terapi
Study of Artemisinin-Based Combination Therapy Patterns in Malaria Patients at Supiori Hospital, Papua
Abstract
Malaria is a disease with high prevalence in Indonesia. According to the Basic Health Research data (Riskesdas) 2018, the province with the highest prevalence of malaria based on the results of blood tests in Indonesia was Papua. The research aims to determine the accuracy of Artemisinin-based combination therapy (ACT) pattern at Supiori Hospital, Papua. Furthermore, a descriptive study and data collection were conducted retrospectively by tracking the treatment history recorded in the patient medical records and other documents. The study was conducted between January–August 2019 and out of 1.636 patients, 71 tested positive for malaria. All patients (100%) were treated with Dyhidroartemisinin-piperaquine (DHP). Falciparum malaria cases were found in 33 people (46.48%), and almost all (96.97%) were treated with DHP+Primaquine. Vivax malaria cases were found in 33 people (46.48%), all of whom (100%) were treated with DHP+Primaquine. Also, mixed malaria cases were found in 5 people (7.04%), 4 people (80.00%) were treated with DHP+Primaquine and 1 person (20.00%) was treated with Artesunate followed by DHP+Primaquine. Furthermore, the pattern of providing malaria therapy at Supiori Hospital in the period January to August 2019 followed the malaria guidelines.
Keywords: Artemisinin-based combination therapy (ACT), malaria, pattern of therapy
Keywords
Full Text:
PDF (Bahasa Indonesia)References
Geleta G, Ketema T. Severe malaria associated with Plasmodium falciparum and P. vivax among children in Pawe Hospital, Northwest Ethiopia. Malar Res Treat. 2016;2016:1240962. doi: 10.1155/2016/1240962
World Health Organization. Guidelines for malaria vector control. Geneva: World Health Organization; 2019.
Siwal N, Singh US, Dash M, Kar S, Rani S, Rawal C, et al. Malaria diagnosis by PCR revealed differential distribution of mono and mixed species infections by Plasmodium falciparum and P. vivax in India. Plos one. 2018;13(3):e0193046. doi: 10.1371/journal.pone.0193046
Kementerian Kesehatan Republik Indonesia. Buku saku tatalaksana kasus malaria. Jakarta: Kementerian Kesehatan Republik Indonesia; 2017.
Kementerian Kesehatan Republik Indonesia. Laporan hasil riset kesehatan dasar Indonesia tahun 2018. Jakarta: Badan Penelitian dan Pengembangan Kesehatan Kemeentrian Kesehatan Republik Indonesia; 2018.
World Health Organization. Guidelines for the treatment of malaria – 3rd edition. Geneva: World Health Organization; 2015.
Lalloo DG, Shingadia D, Bell DJ, Beeching NJ, Whitty CJM, Chiodini PL. UK malaria treatment guidelines 2016. J Infect. 2016;72(6):635–49. doi: 10.1016/j.jinf.2016.02.001
Chirebvu E, Chimbari MJ, Ngwenya BN. Assessment of risk factors associated with malaria transmission in Tubu Village, Northern Botswana. Malar Res Treat. 2014;2014:403069. doi: 10.1155/2014/403069
Schlagenhauf P, Chen LH, Wilson ME, Freedman DO, Tcheng D, Schwartz E, et al. Sex and gender differences in travel-associated disease. Clin Infect Dis. 2010;50(6):826–32. doi: 10.1086/650575
Guyant P, Canavati SE, Chea N, Ly P, Whittaker MA, Feltrer AR, et al. Malaria and the mobile and migrant population in Cambodia: A population movement framework to inform strategies for malaria control and elimination. Malar J. 2015;14(1):252–67. doi: 10.1186/s12936-015-0773-5
Herdiana H, Cotter C, Coutrier FN, Zarlinda I, Zelman BW, Tirta YK, et al. Malaria risk factor assessment using active and passive surveillance data from Aceh Besar, Indonesia, a low endemic, malaria elimination setting with Plasmodium knowlesi, Plasmodium vivax, and Plasmodium falciparum. Malar J. 2016;(15)1:468. doi: 10.1186/s12936-016-1523-z
World Health Organization. World malaria report 2019. Geneva: World Health Organization; 2019.
DOI: https://doi.org/10.15416/ijcp.2021.10.1.30
Refbacks
- There are currently no refbacks.
Indonesian Journal of Clinical Pharmacy is indexed by
